C-reactive proteins and other markers of cardiovascular disease risk.

The acquiring – set to be released in the March 18th on-line edition of Annals of Neurology – can help doctors manage the treatment of individuals with seizures more effectively by prescribing different anti-seizure medications that will not adversely affect cardiovascular wellness. Related StoriesDiabetic retinopathy therapy improvements: an interview with Richard Kirk, CEO of PolyphotonixSingle drop of blood in the mind can activate autoimmune response comparable to multiple sclerosisPresence of tophi in people who have gout can increase threat of developing cardiovascular diseaseThe research involved two of the most widely-prescribed anticonvulsants – phenytoin and carbamazepine – that have potent effects on many enzymes in your body involved in different areas of metabolism.We are very happy with the existing position of Axentis and consider it the right period to present the business to experienced institutional traders. That’s why we are participating within Zurich.’ Related StoriesLung cancer in women: an interview with Harold Wimmer and Chuck BrynelsenDr. Acklin also serves as Vice President Existence Sciences at Venture Valuation AG, a leading independent Swiss company focusing on assessing, valuing and monitoring start-up companies. In this placement Acklin has valued more than 100 life science businesses and recently made a decision to join Axentis. The increasing curiosity in Axentis and its own lead product also led to a presentation at the Biotech Showcase 2009 in SAN FRANCISCO BAY AREA by the company’s CEO Dr.